IBR | Jotup

STL's Optical Connectivity solutions pave the way for digital connectivity in Europe

Retrieved on:

Thursday, March 21, 2024

Optics, Conference, Enclosure, Digital, IBR, IP68, Network, FTTH, STL

BERLIN, March 21, 2024 /PRNewswire/ -- STL (NSE: STLTECH), a leading optical and digital solutions company , today shared the impact of its custom-designed Optical Connectivity solutions for its marquee customers in Europe, at the FTTH Conference 2024 in Berlin, Germany.

Key Points:

BERLIN, March 21, 2024 /PRNewswire/ -- STL (NSE: STLTECH), a leading optical and digital solutions company , today shared the impact of its custom-designed Optical Connectivity solutions for its marquee customers in Europe, at the FTTH Conference 2024 in Berlin, Germany.
Optical Connectivity products, such as terminals, connectors, and enclosures, play a pivotal role in taking fibre connectivity to the premise level, providing scalable solutions to de-skill field installations, and speeding up the fibre deployment process.
STL is one of the few players with end-to-end capability across the fibre value chain, starting with glass preform, different single-mode fibre types, cables and finally, Optical Connectivity solutions.
Our end-to-end optical solutions, including Optical Connectivity, are taking our purpose forward every day.

PreludeDx™ to Present Data in DCIS and Stage I, II Early Breast Cancer at the 2024 Miami Breast Cancer Conference

Retrieved on:

Thursday, February 22, 2024

Cleveland Clinic, Therapy, DCIS, MD, IBR, MBCC, Conference, Radiation, Medicine, Patient, Impact, Radiation therapy, Woman, Medical imaging

LAGUNA HILLS, Calif., Feb. 22, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that data will be highlighted in three separate poster presentations at the 2024 Miami Breast Cancer Conference (MBCC), held on March 7 – 10, 2024 at the Fontainebleau, Miami Beach, FL.

Key Points:

LAGUNA HILLS, Calif., Feb. 22, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that data will be highlighted in three separate poster presentations at the 2024 Miami Breast Cancer Conference (MBCC), held on March 7 – 10, 2024 at the Fontainebleau, Miami Beach, FL.
"We are excited to share data regarding our novel biosignature for invasive Stage I, II breast cancer test for radiation therapy, as well as clinical utility data on our DCISionRT test for DCIS at the prestigious MBCC conference," said Dan Forche, President and CEO of PreludeDx.
"We look forward to connecting with colleagues and sharing our vision for future early-stage breast cancer products, as well as advancing collaboration opportunities."
Title: Impact on Radiation Therapy Recommendation and Treatment Modality for Patients with Ductal Carcinoma in Situ Using the 7-Gene Biosignature: Analysis of the PREDICT Study
Presenter: Chirag S. Shah, MD, Co-Director of Breast Radiation Oncology, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
Title: Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women with Low-Risk DCIS after Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-year Ipsilateral Breast Recurrence (IBR) Rates
Presenter: Frank A. Vicini, MD, FASTRO, Radiation Oncologist at Michigan HealthCare Professionals, member of NRG Oncology

HFCL Launches a Suite of Connectivity Products and Solutions for Global Telcos and Enterprises

Retrieved on:

Monday, October 30, 2023

HFCL has unveiled its own designed and developed 5G FWA (Fixed Wireless Access) CPE (Customer Premise Equipment) solution in various variants.

Key Points:

HFCL has unveiled its own designed and developed 5G FWA (Fixed Wireless Access) CPE (Customer Premise Equipment) solution in various variants.
Pioneering innovative technology products, HFCL’s portfolio of Indoor and Outdoor 5G FWA CPE products will accelerate wireless broadband penetration in urban, rural areas and help bridge the last-mile connectivity challenge in key global markets.
Further, addressing the connectivity needs and bandwidth challenges faced by telcos and enterprises in the fast-evolving digital landscape, HFCL has also launched revolutionary IP MPLS Routers.
With the launch of these revolutionary products, we continue on our mission to build a sustainable global digital economy.”

IFF Announces Clariant Has Agreed to Purchase IFF’s Cosmetic Ingredients Business Unit

Retrieved on:

Monday, October 30, 2023

IFF (NYSE: IFF) today announced that Clariant—a sustainably focused specialty chemical company—has agreed to purchase IFF’s Cosmetic Ingredients business unit for $810 million.

Key Points:

IFF (NYSE: IFF) today announced that Clariant—a sustainably focused specialty chemical company—has agreed to purchase IFF’s Cosmetic Ingredients business unit for $810 million.
Reporting through IFF’s Scent division, IFF’s Cosmetic Ingredients business unit develops, manufactures and markets innovative ingredients for the cosmetic and personal care industry, including active ingredients, functional ingredients and delivery systems, primarily through the Lucas Meyer Cosmetics brand.
“Aligned with our best-owner mindset, the proposed sale of our Cosmetic Ingredients business to Clariant will allow us to focus on our core businesses, maximizing growth and returns.
We are convinced that Clariant is the best owner for the Cosmetic Ingredients business and with an ability to invest, will offer the business and our colleagues a bright future.”
IFF’s Cosmetic Ingredients business unit includes the Lucas Meyers Cosmetics and IBR brands and operates six research and development and/or production sites globally.

HFCL launches a suite of connectivity products and solutions for global telcos and enterprises

Retrieved on:

Monday, October 30, 2023

TCO, Data-rate units, Quality of service, HFCL, FTTH, IBR, QOS, Customer, India Mobile Congress, Citizens band radio in India, City, UBR, NSA, FWA, Wireless, IP, CPE, High-pass filter, Cable television

HFCL has unveiled its own designed and developed 5G FWA (Fixed Wireless Access) CPE (Customer Premise Equipment) solution in various variants.

Key Points:

HFCL has unveiled its own designed and developed 5G FWA (Fixed Wireless Access) CPE (Customer Premise Equipment) solution in various variants.
Pioneering innovative technology products, HFCL's portfolio of Indoor and Outdoor 5G FWA CPE products will accelerate wireless broadband penetration in urban, rural areas and help bridge the last-mile connectivity challenge in key global markets.
Further, addressing the connectivity needs and bandwidth challenges faced by telcos and enterprises in the fast-evolving digital landscape, HFCL has also launched revolutionary IP MPLS Routers.
With the launch of these revolutionary products, we continue on our mission to build a sustainable global digital economy."

COMSovereign's Fastback Intelligent Backhaul Radios Deployed at the Nation's Leading Travel Stop Network to Dramatically Improving Connectivity

Retrieved on:

Thursday, October 19, 2023

NLOS, Women Deliver, IBR, Organization, Internet access, Artificial intelligence, Internet, The Company, LTE Advanced, LOS, Data-rate units, Travel, COMS, Fastback, Mobile phone

TUCSON, Ariz., Oct. 19, 2023 /PRNewswire/ -- COMSovereign Holding Corp. (NASDAQ: COMS and COMSP) ("COMSovereign" or the "Company"), a U.S.-based developer of 4G LTE Advanced and 5G communication systems and solutions today announced the successful deployment of its Fastback Intelligent Backhaul Radios ("IBRs") with the nation's leading travel stop network. Sales and deployment at this new customer were conducted in collaboration with a leading wireless integrator partner who develops custom services for complex networks operated by service providers, large enterprises, and government entities. COMSovereign Fastback IBR 1300 is the Company's high-performance last mile connectivity solution operating in the unlicensed frequency spectrum.

Key Points:

COMSovereign Fastback IBR 1300 is the Company's high-performance last mile connectivity solution operating in the unlicensed frequency spectrum.
Existing wired and wireless connectivity solutions proved cumbersome, inflexible, difficult to manage, and did not provide the reliable internet access and redundancy the customer required.
Working closely with the customer, our systems integrator partner was able to deploy the Fastback IBR radios at their customers' locations, rapidly providing high-speed wireless datalinks.
For more information about COMSovereign, please visit www.COMSovereign.com and connect with us on Facebook and Twitter .

PreludeDx™ Presents Risk Assessments for DCIS Patients Using Clinicopathologic-Based Models Like RTOG 9804 and MSKCC Compared to DCISionRT®

Retrieved on:

Monday, October 2, 2023

These DCISionRT High-Risk patients had high 10-year ipsilateral breast recurrence (IBR) rates and significant radiation therapy (RT) benefit.

Key Points:

These DCISionRT High-Risk patients had high 10-year ipsilateral breast recurrence (IBR) rates and significant radiation therapy (RT) benefit.
In contrast, the corresponding DCISionRT Low-Risk patients had low 10-yr IBR rates and no significant RT benefit.
“Prior to DCISionRT, we relied primarily on traditional clinicopathologic factors to make treatment decisions.
Conversely, the study also demonstrated patients reclassified into the DCISionRT High-Risk groups had higher IBR rates without RT (20% and 12%) and significant absolute IBR rate reductions (13% and 8%) from RT.

ACMI Properties to Lead Development of Pilot Munitions Campus

Retrieved on:

Wednesday, September 27, 2023

AUSTIN, Texas, Sept. 27, 2023 /PRNewswire/ -- ACMI Properties, a division of the American Center for Manufacturing and Innovation (ACMI), has announced it will spearhead the development and construction of a new industrial campus focused on munitions. The initiative is part of a $75 million Department of Defense (DoD) contract awarded to ACMI Federal to support the initial campus by the DoD's Office of the Deputy Assistant Secretary of Defense for Industrial Base Resilience (IBR) through its Manufacturing Capability Expansion and Investment Prioritization (MCEIP) Directorate.

Key Points:

AUSTIN, Texas, Sept. 27, 2023 /PRNewswire/ -- ACMI Properties, a division of the American Center for Manufacturing and Innovation (ACMI), has announced it will spearhead the development and construction of a new industrial campus focused on munitions.
"ACMI Properties is pioneering a new model for the hardware innovation cluster," says Simon Shewmaker, Head of Development for ACMI Properties.
For Munitions Campus, ACMI seeks to enable these firms with key capabilities necessary for munitions development and production.
ACMI Properties is already in planning stages for additional campus projects with a focus on battery manufacturing, space and hypersonic system.

ACMI Federal Secures $75 Million DoD Contract for Munitions Campus to Strengthen Munitions Supply Chain

Retrieved on:

Tuesday, September 26, 2023

Using a public-private partnership framework, the initiative will bolster the United States' manufacturing capabilities in areas vital for national defense.

Key Points:

Using a public-private partnership framework, the initiative will bolster the United States' manufacturing capabilities in areas vital for national defense.
This pilot constitutes a core component of MCEIP's five-year roadmap designed to secure supply chain resiliency and fortify the defense industrial base.
"ACMI Federal is privileged to lead this critical endeavor," said John Burer, Founder of ACMI.
The Munitions Campus will support companies by providing a range of key resources necessary for munitions development and production, such as non-destructive inspection, explosives storage and transportation, prototype testing, and munitions manufacturing tools.

PreludeDx™ to Present New DCISionRT® Comparative Data in Oral Session at ASTRO 2023 Annual Meeting

Retrieved on:

Tuesday, September 19, 2023

San Diego Convention Center, Cleveland Clinic, Impact, ASTRO, OH, Radiation, Woman, Radiation therapy, Ductal carcinoma, Therapy, IBR, MD, Medicine, Pregnancy Outcome Prediction study, DCIS, Patient, Society, American Society for Radiation Oncology, Medical imaging

LAGUNA HILLS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will be presenting data using DCISionRT to identify limitations in current clinicopathologic factors alone to predict radiation benefit in women with ductal carcinoma in situ (DCIS).

Key Points:

LAGUNA HILLS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will be presenting data using DCISionRT to identify limitations in current clinicopathologic factors alone to predict radiation benefit in women with ductal carcinoma in situ (DCIS).
This comparison data was selected for a scientific session oral presentation at the 65th Annual American Society for Radiation Oncology (ASTRO) Meeting, to be held on October 1-4, 2023 at the San Diego Convention Center, San Diego, CA.
“We are pleased to have our new comparison data on DCISionRT selected for oral presentation at the prestigious ASTRO Annual Meeting,” said Dan Forche, President and CEO of PreludeDx.
“This new data is being presented by Dr. Frank A. Vicini, who will share how this data further validates the value of DCISionRT in guiding treatment decisions for DCIS patients.”
Title: Number 100: Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women with Low-Risk DCIS after Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-year Ipsilateral Breast Recurrence (IBR) Rates
Presenter: Frank A. Vicini, MD, FASTRO, Radiation Oncologist at Michigan HealthCare Professionals, member of NRG Oncology, and first author of the study
Title: Number 2439: Impact on Radiation Therapy Recommendation and Treatment Modality for Patients with Ductal Carcinoma in Situ Using the 7-Gene Biosignature: Analysis of the PREDICT Study
Presenter: Chirag S. Shah, MD, Director of Breast Radiation Oncology, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH